Screening Pfizer's compound library resulted in the identification of weak acetyl-CoA carboxylase inhibitors, from which were obtained rACC1 CT-domain co-crystal structures. Utilizing HTS hits and structure-based drug discovery, a more rigid inhibitor was designed and led to the discovery of sub-micromolar, spirochromanone non-specific ACC inhibitors. Low nanomolar, non-specific ACC-isozyme inhibitors that exhibited good rat pharmacokinetics were obtained from this chemotype.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2009.04.091 | DOI Listing |
Publication Analysis
Top Keywords
acetyl-coa carboxylase
8
discovery small
4
small molecule
4
molecule isozyme
4
isozyme non-specific
4
inhibitors
4
non-specific inhibitors
4
inhibitors mammalian
4
mammalian acetyl-coa
4
carboxylase screening
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!